Fig. 4
Comparison between patients with baseline plasma KL-6 < 2.5 ng/mL with patients with KL-6 ≥ 2.5 ng/mL in: a annual rate of FVC decline; b annual rate of DLCO decline; c annual rate of FVC decline after excluding patients with AE-IPF; d annual rate of DLCO decline after excluding patients with AE-IPF; e proportion of patients with ≥ 5% FVC decline over 24 weeks; f proportion of patients with ≥ 10% DLCO decline over 24 weeks. In panels a to d, data are presented as medians with inter-quartile ranges, and p-values were derived from the Mann Whitney U test. In panels e and f, data shown are proportions of patients in each subgroup, and p-values were derived from Fisher’s exact test. Abbreviation AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; DLCO, diffusion capacity for carbon monoxide; FVC, forced vital capacity; KL-6, Krebs von den Lungen-6